Additionally, the investigation of hub CRDEGs–drugs interactions revealed potential therapeutic targets, exemplified by DLAT and PDHA1, capable of impeding AAA progression (Figure 5H). This evidence concerns the gene PDHA1 and triple-A syndrome.